Shots:

• The cohort 16 of the P-Ib (COSMIC-021) trial of cabozantinib + atezolizumab in patients with metastatic colorectal cancer showed the median follow-up of 28.1mos., ORR (10%); DCR (71%); m-PFS (3.0mos.); m-OS (14.0mos.); mDoR (7.6mos.), clinical activity & a manageable safety profile
• The cohort 2 of the P-II (CAMILLA) trial of cabozantinib + durvalumab in 36 patients with advanced pMMR/MSS colorectal cancer showed that 29 patients were evaluable for efficacy analysis, ORR (27.6%); PRR (20.7%); DCR (86.2%), m-PFS (3.8mos.) with a 6mos. PFS (34.5%); m-OS (9.1mos.), was well tolerated with no new safety signals
• Cabometyx has been approved in the EU & additional countries and regions globally

Ref: Exelixis | Image: Wikipedia